Bausch + Lomb to buy ‘dry eye’ treatment from Novartis in a $2.5 billion deal

Bausch + Lomb's stock leapt Friday, after the eye-health products company announced a $2.5 billion deal to buy Novartis' "dry eye" treatment Xiidra.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.